Program
orforglipron
Also written as “Orforglipron”, “LY3502970” and “[14C]-LY3502970”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Obesity, Abdominal · Renal Insufficiency, Chronic, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 5017 open or running | phase 3since Mar 27, 2023 | Apr 25, 2019 | Feb 2027phase 3 · NCT06672549 |
Also a collaborator on its studies: quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 28 studies since Apr 25, 2019.
- May 29, 2024Phase 1 study in ObesityNCT06440980 · 533 enrolled · United States
- Sep 3, 2024Phase 3 study in ObesityNCT06584916 · 376 enrolled · United States, Puerto Rico
- Oct 17, 2024Phase 3 study in OverweightNCT06649045 · 712 enrolled · United States, Argentina, Brazil and more
- Nov 1, 20242 phase 3 studies in ObesityNCT06672939, NCT06672549
- Nov 14, 20242 phase 1 studies in HealthyNCT06692348, NCT06704763
- Jan 27, 2025Phase 1 study in ObesityNCT06824051 · 120 enrolled · United States
- Apr 21, 20253 phase 3 studies in HypertensionNCT06952530, NCT06948435, NCT06948422
- May 7, 20253 phase 3 studies in ObesityNCT06993792, NCT06972472, NCT06972459
- Sep 2, 20252 phase 3 studiesNCT07153471, NCT07202884
- Oct 30, 2025Phase 3 study in Peripheral Arterial DiseaseNCT07223593 · 1,205 planned · United States, Argentina, Australia and more
- Nov 17, 2025Phase 3 study in Renal Insufficiency, ChronicNCT07241390 · 7,140 planned · Argentina, Australia, Austria and more
- May 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07613307 · 130 planned · India, Saudi Arabia, South Africa and more
- Jun 22, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07668336 · 170 planned · United States, Belgium, Brazil and more
- Aug 25, 20262 phase 3 studiesNCT07790861, NCT07794579
Ahead
- Feb 2027Primary completion: phase 3 study in ObesityNCT06672549
- May 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07613307
- Aug 2027Primary completion: phase 3 study in ObesityNCT06993792
- Aug 2027Primary completion: phase 3 study in ObesityNCT06972472
TargetBeta
“Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that was approved by the U.S.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07794579Overweight · United States, Argentina, China and more | 3 | Recruiting | Aug 2029 | 2,001 |
| NCT07790861Obesity · China | 3 | Not yet recruiting | Mar 2028 | 192 |
| NCT07668336Diabetes Mellitus, Type 2 · United States, Belgium, Brazil and more | 3 | Recruiting | Mar 2030 | 170 |
| NCT07613307Diabetes Mellitus, Type 2 · India, Saudi Arabia, South Africa and more | 3 | Recruiting | May 2027 | 130 |
| NCT07241390Renal Insufficiency, Chronic · Argentina, Australia, Austria and more | 3 | Recruiting | Aug 2031 | 7,140 |
| NCT07223593Peripheral Arterial Disease · United States, Argentina, Australia and more | 3 | Recruiting | Jun 2028 | 1,205 |
| NCT07202884Urinary Incontinence, Stress · United States, Canada, China and more | 3 | Recruiting | Mar 2028 | 1,000 |
| NCT07153471Osteoarthritis · United States, Canada, China and more | 3 | Active, not recruiting | Apr 2028 | 800 |
| NCT06993792Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 1,400 |
| NCT06972472Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 600 |
| NCT06972459Obesity · United States, Argentina, China and more | 3 | Active, not recruiting | Aug 2027 | 800 |
| NCT06952530Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 487 |
| NCT06948435Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 487 |
| NCT06948422Hypertension · United States, Argentina, China and more | 3 | Active, not recruiting | Sep 2027 | 974 |
| NCT06824051Obesity · United States | 1 | Completed | Jan 26, 2026 | 120 |
| NCT06704763Healthy · United States | 1 | Completed | Feb 5, 2025 | 27 |
| NCT06692348Healthy · Japan | 1 | Completed | Jun 9, 2025 | 86 |
| NCT06672939Obesity · United States, Israel, Italy and more | 3 | Recruiting | Dec 2027 | 150 |
| NCT06672549Obesity · United States, Belgium, Brazil and more | 3 | Recruiting | Feb 2027 | 125 |
| NCT06649045Overweight · United States, Argentina, Brazil and more | 3 | Completed | Jul 21, 2026 | 712 |
| NCT06584916Obesity · United States, Puerto Rico | 3 | Completed | Nov 21, 2025 | 376 |
| NCT06440980Obesity · United States | 1 | Completed | Jun 2, 2025 | 533 |
| NCT06370728Healthy · United States | 1 | Completed | Jul 23, 2024 | 30 |
| NCT06192108Diabetes Mellitus, Type 2 · United States, China, Germany and more | 3 | Completed | Sep 26, 2025 | 962 |
| NCT06186622Obesity · United States | 1 | Completed | Jul 10, 2024 | 50 |
| NCT06109311Diabetes Mellitus, Type 2 · United States, Brazil, China and more | 3 | Completed | Sep 15, 2025 | 546 |
| NCT06085482Healthy · United States | 1 | Completed | Jan 5, 2024 | 10 |
| NCT06045221Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Completed | Aug 22, 2025 | 1,698 |
| NCT06023095Overweight · China | 1 | Completed | Jul 29, 2024 | 24 |
| NCT06010004Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Jun 5, 2025 | 401 |
| NCT05971940Diabetes Mellitus, Type 2 · United States, China, India and more | 3 | Completed | Apr 3, 2025 | 559 |
| NCT05936138Renal Insufficiency · United States | 1 | Completed | Apr 11, 2024 | 24 |
| NCT05931380Obesity · Japan | 3 | Completed | Jun 19, 2025 | 238 |
| NCT05882032Hepatic Insufficiency · United States | 1 | Completed | Nov 18, 2024 | 29 |
| NCT05872620Obesity · United States, Argentina, Australia and more | 3 | Completed | Aug 8, 2025 | 1,613 |
| NCT05869903Obesity · United States, Brazil, China and more | 3 | Active, not recruiting | Jul 25, 2025 | 3,127 |
| NCT05841238Obesity · United States | 1 | Completed | Sep 14, 2023 | 52 |
| NCT05803421Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Mar 16, 2026 | 2,749 |
| NCT05573230Healthy · Singapore | 1 | Completed | Jan 17, 2023 | 32 |
| NCT05469126Healthy · Singapore | 1 | Completed | Nov 3, 2022 | 26 |
| NCT05341089Healthy · Singapore | 1 | Completed | Sep 1, 2022 | 39 |
| NCT05313802Obesity · United States | 1 | Completed | Sep 9, 2022 | 72 |
| NCT05110794Healthy · Singapore | 1 | Completed | Feb 10, 2022 | 34 |
| NCT05086445Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Sep 5, 2022 | 62 |
| NCT05051579Obesity · United States, Canada, Hungary and more | 2 | Completed | Aug 25, 2022 | 272 |
| NCT05051566Healthy · United Kingdom | 1 | Completed | Apr 4, 2022 | 26 |
| NCT05048719Diabetes Mellitus, Type 2 · United States, Hungary, Poland and more | 2 | Completed | Sep 30, 2022 | 383 |
| NCT04680767Healthy · United Kingdom | 1 | Completed | Jul 3, 2021 | 6 |
| NCT04426474Diabetes Mellitus, Type 2 · United States, Germany | 1 | Completed | Jul 12, 2021 | 68 |
| NCT03929744Healthy · United States | 1 | Completed | Nov 2, 2020 | 133 |
How it is read
Names in the registry
- “Orforglipron”, 33 entries
- “LY3502970”, 16 entries
- “[14C]-LY3502970”, 1 entry
- “[¹⁴C]-LY3502970”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 18 studies
- Diabetes Mellitus, Type 2, 11 studies
- Hypertension, 3 studies
- Obesity, Abdominal, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.